A Phase 3 interventional study of Follitropin delta and Follitropin beta in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 17 sites in Japan. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-08-24.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 5th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2017.
This study's enrollment of 373 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2017, is one of 11 in phase 3, and was the 26th registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate non-inferiority of FE 999049 compared to FOLLISTIM with respect to number of oocytes retrieved in Japanese IVF/ICSI patients undergoing controlled ovarian stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
Drug: Follitropin delta
FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
Drug: Follitropin beta
Single daily subcutaneous administration through pre-filled injection pen
Also known as: FE 999049, REKOVELLE
Single daily subcutaneous injection in the abdomen
Also known as: FOLLISTIM
Number of Oocytes Retrieved
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
Time frame: 36h (± 2h) after triggering of final follicular maturation (On day of oocyte retrieval)
Clinical Pregnancy Rate
Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.
Time frame: 5-6 weeks after transfer (up to approximately 3 months after start of stimulation)
Positive Beta Unit of Human Chorionic Gonadotropin (Beta-hCG) Rate
Defined as positive serum beta-hCG test 13-15 days after transfer.
Time frame: 13-15 days after transfer (up to approximately 1.5 months after start of stimulation)
Vital Pregnancy Rate
Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer.
Time frame: 5-6 weeks after transfer (up to approximately 3 months after start of stimulation)
Implantation Rate
Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by the number of blastocysts transferred.
Time frame: 5-6 weeks after transfer (up to approximately 3 months after start of stimulation)
Proportion of Participants With Cycle Cancellation Due to Poor or Excessive Ovarian Response
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion of Participants With Blastocyst Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion of Participants With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
Defined as proportion of participants grouped according to the number of oocytes retrieved. The proportion of participants with \<4 oocytes (low response), 4-7 oocytes (moderate response), 8-14 oocytes (targeted response), 15-19 oocytes (hyperresponse) and ≥20 oocytes (severe hyperresponse) are presented.
Time frame: On the day of oocyte retrieval (up to 22 days after start of stimulation)
Proportion of Participants With Extreme Ovarian Responses (Defined as <4, ≥15 or ≥20 Oocytes Retrieved) in Risk Population
Time frame: On the day of oocyte retrieval (up to 22 days after start of stimulation)
Proportion of Participants With Preventive Interventions for Early Ovarian Hyperstimulation Syndrome (OHSS)
Time frame: ≤9 days after triggering of final follicular maturation
Proportions of Participants With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS
Defined as proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.
Time frame: Up to 9 days after triggering of final follicular maturation
Proportions of Participants With Late OHSS (Including OHSS of Moderate/Severe Grade)
Defined as proportions of participants with late OHSS (including OHSS of moderate/severe grade). Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade are presented. All OHSS cases were graded as mild, moderate, or severe.
Time frame: >9 days after triggering of final follicular maturation
Number of Follicles on Stimulation Day 6
Defined as the number of follicles observed in both ovaries at the last transvaginal ultrasound (TVUS) in the stimulation phase (on stimulation Day 6).
Time frame: At Day 6 of stimulation
Number of Follicles at End-of-stimulation
Defined as the number of follicles observed in both ovaries at the last TVUS in the stimulation phase (end-of-stimulation).
Time frame: End-of-stimulation (up to 20 stimulation days)
Size of Follicles on Stimulation Day 6
Defined as size characteristics of follicles on stimulation Day 6. Average size of 3 largest follicles has been presented in this endpoint.
Time frame: At Day 6 of stimulation
Size of Follicles at End-of-Stimulation
Defined as size characteristics of follicles at end-of-stimulation. Average size of 3 largest follicles has been presented in this endpoint.
Time frame: End-of-stimulation (up to 20 stimulation days)
Fertilization Rate
The fertilization rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved.
Time frame: Day 1 after oocyte retrieval (up to approximately 22 days after start of stimulation)
Number and Quality of Embryos
Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3.
Time frame: Day 3 after oocyte retrieval (up to approximately 24 days after start of stimulation)
Number and Quality of Blastocysts
Number of embryos (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
Time frame: Day 5 after oocyte retrieval (up to approximately 26 days after start of stimulation)
Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) on Stimulation Day 6
The median and inter-quartile range (IQR) of FSH and LH levels on stimulation Day 6 are presented.
Time frame: At Day 6 of stimulation
Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) at End-of-stimulation
The median and IQR of FSH and LH levels at end-of-stimulation are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Circulating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 6
The median and IQR of estradiol levels on stimulation Day 6 are presented.
Time frame: At Day 6 of stimulation
Circulating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation
The median and IQR of estradiol levels at end-of-stimulation are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Circulating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 6
The median and IQR of progesterone levels on stimulation Day 6 are presented.
Time frame: At Day 6 of stimulation
Circulating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation
The median and IQR of progesterone levels at end-of-stimulation are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Circulating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6
The median and IQR of Inhibin A levels on stimulation Day 6 are presented.
Time frame: At Day 6 of stimulation
Circulating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation
The median and IQR of Inhibin A levels at end-of-stimulation are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Circulating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6
The median and IQR of inhibin B levels on stimulation Day 6 are presented.
Time frame: At Day 6 of stimulation
Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation
The median and IQR of inhibin B levels at end-of-stimulation are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Number of Stimulation Days
Time frame: End-of-stimulation (up to 20 stimulation days)
Total Gonadotropin Dose of FE 999049
Time frame: End-of-stimulation (up to 20 stimulation days)
Total Gonadotropin Dose of FOLLISTIM
Time frame: End-of-stimulation (up to 20 stimulation days)
Number of Participants With Adverse Events (AEs) Stratified by Intensity
The frequency of participants with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented. An AE was any untoward medical occurrence in a participants participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity); moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable).
Time frame: From signed informed consent up to 5-6 weeks after transfer
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-stimulation
Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation
Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial
Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.
Time frame: Up to 5-6 weeks after transfer
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-trial
Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.
Time frame: Up to 5-6 weeks after transfer
Frequency and Intensity of Injection Site Reactions
The presence of of injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after the injection are presented. The injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Technical Malfunctions of the Administration Pens
Time frame: End-of-stimulation (up to 20 stimulation days)
A total of 17 investigational sites in Japan randomized participants to the trial between 29 July 2017 to 08 July 2019.
| Milestone | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Started | 170 | 178 |
| Completed | 147 | 143 |
| Not completed | 23 | 35 |
| Withdrew: Adverse event | 13 | 18 |
| Withdrew: Randomization failure | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other | 9 | 16 |
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
| Oocytes retrieved | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Number of Oocytes Retrieved | 9.3 ± 5.4 | 10.5 ± 6.1 |
Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Clinical Pregnancy Rate | 25.3 | 23.7 |
Defined as positive serum beta-hCG test 13-15 days after transfer.
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Positive Beta Unit of Human Chorionic Gonadotropin (Beta-hCG) Rate | 29.4 | 29.4 |
Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer.
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Vital Pregnancy Rate | 23.5 | 21.5 |
Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by the number of blastocysts transferred.
| % of sacs/blastocysts transferred | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Implantation Rate | 31.9 | 29.8 |
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Cycle cancelled due to poor ovarian response | 1.2 | 0.6 |
| Cycle cancelled due to excessive ovarian response | 0 | 1.1 |
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Proportion of Participants With Blastocyst Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk | 7.6 | 11.3 |
Defined as proportion of participants grouped according to the number of oocytes retrieved. The proportion of participants with \<4 oocytes (low response), 4-7 oocytes (moderate response), 8-14 oocytes (targeted response), 15-19 oocytes (hyperresponse) and ≥20 oocytes (severe hyperresponse) are presented.
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Low response (<4 oocytes) | 8.3 | 5.2 |
| Moderate response (4-7 oocytes) | 36.1 | 26.6 |
| Targeted response (8-14 oocytes) | 40.8 | 42.8 |
| Hyperresponse (15-19 oocytes) | 10.1 | 14.5 |
| Severe hyperresponse (≥ 20 oocytes) | 4.7 | 11.0 |
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| AMH < 15 pmol/L (<4 oocytes retrieved) | 11.6 | 12.3 |
| AMH >= 15 pmol/L (>=15 oocytes retrieved) | 22.0 | 42.0 |
| AMH >= 15 pmol/L (>=20 oocytes retrieved) | 8.0 | 19.0 |
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Cycle cancellation | 0 | 1.1 |
| Triggering with GnRH agonist | 1.2 | 1.1 |
| Administration of dopamine agonist | 0.6 | 1.7 |
Defined as proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Early OHSS (any grade) | 10.0 | 18.6 |
| Early OHSS (moderate/severe) | 6.5 | 13.0 |
| Early OHSS (any grade) and/or preventive | 10.6 | 20.9 |
| Early OHSS (moderate/severe) and/or preventive | 7.6 | 16.4 |
Defined as proportions of participants with late OHSS (including OHSS of moderate/severe grade). Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade are presented. All OHSS cases were graded as mild, moderate, or severe.
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Late OHSS (any grade) | 1.2 | 1.1 |
| Late OHSS (moderate/severe) | 0.6 | 1.1 |
Defined as the number of follicles observed in both ovaries at the last transvaginal ultrasound (TVUS) in the stimulation phase (on stimulation Day 6).
| Follicles | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Number of Follicles on Stimulation Day 6 | 12.8 ± 7.2 | 13.3 ± 7.1 |
Defined as the number of follicles observed in both ovaries at the last TVUS in the stimulation phase (end-of-stimulation).
| Follicles | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Number of Follicles at End-of-stimulation | 14.9 ± 8.0 | 16.3 ± 8.8 |
Defined as size characteristics of follicles on stimulation Day 6. Average size of 3 largest follicles has been presented in this endpoint.
| mm | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Size of Follicles on Stimulation Day 6 | 12.7 ± 2.1 | 12.8 ± 2.0 |
Defined as size characteristics of follicles at end-of-stimulation. Average size of 3 largest follicles has been presented in this endpoint.
| mm | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Size of Follicles at End-of-Stimulation | 19.2 ± 1.5 | 19.4 ± 1.6 |
The fertilization rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved.
| percentage of fertilized oocytes | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Fertilization Rate | 54.5 ± 26.1 | 57.1 ± 23.4 |
Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3.
| Embryo | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Number of embryo | 5.8 ± 4.2 | 7.0 ± 4.3 |
| Number of good-quality embryo | 3.9 ± 3.3 | 4.6 ± 3.3 |
Number of embryos (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
| Blastocysts | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Number of blastocysts | 3.1 ± 2.7 | 4.2 ± 3.4 |
| Number of good-quality blastocysts | 2.3 ± 2.3 | 3.0 ± 2.6 |
The median and inter-quartile range (IQR) of FSH and LH levels on stimulation Day 6 are presented.
| IU/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| FSH | 15.4 (12.0 to 19.6) | 14.7 (12.8 to 17.3) |
| LH | 2.6 (1.5 to 6.2) | 2.8 (1.6 to 5.9) |
The median and IQR of FSH and LH levels at end-of-stimulation are presented.
| IU/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| FSH | 14.3 (11.6 to 19.7) | 16.4 (13.5 to 20.4) |
| LH | 1.6 (1.0 to 2.5) | 1.4 (0.9 to 2.3) |
The median and IQR of estradiol levels on stimulation Day 6 are presented.
| pmol/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 6 | 2277.1 (1479.4 to 3580.1) | 2680.0 (1608.8 to 4685.9) |
The median and IQR of estradiol levels at end-of-stimulation are presented.
| pmol/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation | 6517.0 (4465.3 to 9033.4) | 7438.8 (5363.6 to 10283.1) |
The median and IQR of progesterone levels on stimulation Day 6 are presented.
| nmol/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 6 | 1.7 (0.8 to 2.4) | 1.7 (0.8 to 2.65) |
The median and IQR of progesterone levels at end-of-stimulation are presented.
| nmol/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation | 2.5 (1.9 to 3.5) | 3.1 (2.3 to 4.3) |
The median and IQR of Inhibin A levels on stimulation Day 6 are presented.
| ng/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6 | 113.1 (75.1 to 171.9) | 129.8 (81.6 to 210.6) |
The median and IQR of Inhibin A levels at end-of-stimulation are presented.
| ng/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation | 323.8 (222.1 to 458.8) | 390.3 (301.0 to 551.1) |
The median and IQR of inhibin B levels on stimulation Day 6 are presented.
| ng/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6 | 570.5 (396.0 to 853.0) | 686.0 (431.0 to 1004.0) |
The median and IQR of inhibin B levels at end-of-stimulation are presented.
| ng/L | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation | 686.0 (461.0 to 1057.0) | 734.5 (492.5 to 1120.5) |
| Days | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Number of Stimulation Days | 8.9 ± 1.9 | 8.8 ± 1.7 |
| μg | FE 999049 (Follitropin Delta) |
|---|---|
| Total Gonadotropin Dose of FE 999049 | 83.5 ± 28.9 |
| IU | FOLLISTIM (Follitropin Beta) |
|---|---|
| Total Gonadotropin Dose of FOLLISTIM | 1499 ± 514 |
The frequency of participants with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented. An AE was any untoward medical occurrence in a participants participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity); moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable).
| Participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Any AE | 73 | 92 |
| Mild AE | 69 | 86 |
| Moderate AE | 8 | 12 |
| Severe AE | 0 | 1 |
Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.
| participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| ALT (IU/L): Normal to markedly high (>3xULN) | 0 | 1 |
| AST (IU/L): Normal to markedly high (>3xULN) | 0 | 1 |
Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.
| participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation | 0 | 0 |
Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.
| participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial | 0 | 0 |
Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.
| participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Leukocytes (10^9/L) Normal to markedly high (>=16) | 0 | 1 |
| Hemoglobin (g/L) Normal to markedly low | 0 | 1 |
| Hematocrit (ratio) Normal to markedly low (>=0.56) | 0 | 1 |
The presence of of injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after the injection are presented. The injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.
| events | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Any mild injection site reaction | 271 | 719 |
| Any moderate injection site reaction | 7 | 19 |
| Any severe injection site reaction | 1 | 0 |
| Mild redness | 140 | 174 |
| Moderate redness | 2 | 0 |
| Severe redness | 0 | 0 |
| Mild itching | 4 | 5 |
| Moderate itching | 1 | 0 |
| Severe itching | 0 | 0 |
| Mild pain | 19 | 411 |
| Moderate pain | 1 | 16 |
| Severe pain | 0 | 0 |
| Mild swelling | 6 | 10 |
| Moderate swelling | 0 | 0 |
| Severe swelling | 0 | 0 |
| Mild bruising | 102 | 119 |
| Moderate bruising | 3 | 3 |
| Severe bruising | 1 | 0 |
| percentage of participants | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Technical Malfunctions of the Administration Pens | 0 | 0 |
Collected over Adverse events were monitored from the time of obtaining informed consent until the last visit (end-of-trial) (up to approximately 2 years) .. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 (Follitropin Delta) | 0/170 (0%) | 0/170 (0%) | 73/170 (42.9%) |
| FOLLISTIM (Follitropin Beta) | 0/177 (0%) | 2/177 (1.1%) | 92/177 (52%) |
| Event | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 0/170 | 2/177 |
| Event | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 19/170 | 35/177 |
| Injection site erythemaGeneral disorders | 13/170 | 15/177 |
| Biochemical pregnancyPregnancy, puerperium and perinatal conditions | 6/170 | 10/177 |
| Ovarian cystReproductive system and breast disorders | 5/170 | 7/177 |
| Viral upper respiratory tract infectionInfections and infestations | 6/170 | 6/177 |
| Ovarian enlargementReproductive system and breast disorders | 5/170 | 5/177 |
| ConstipationGastrointestinal disorders | 4/170 | 5/177 |
| Injection site pruritusGeneral disorders | 0/170 | 5/177 |
| HeadacheNervous system disorders | 4/170 | 4/177 |
| Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions | 4/170 | 0/177 |
| Age, Continuous(years) | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) | Total |
|---|---|---|---|
| Mean | 34.2 ± 3.5 | 34.0 ± 3.4 | 34.1 ± 3.5 |
| Sex: Female, Male(Participants) | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) | Total |
|---|---|---|---|
| Female | 170 | 177 | 347 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 170 | 177 | 347 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 170 | 177 | 347 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | FE 999049 (Follitropin Delta) | FOLLISTIM (Follitropin Beta) | Total |
|---|---|---|---|
| Japan | 170 | 177 | 347 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Jun 2019, 22 months.
Results were first posted in Mar 2021, 1 year 9 months after primary completion.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 22 months is above that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta